Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2016

View Archived Issues

Arbutus initiates phase IIa study of ARB-001467 for chronic HBV

MedImmune initiates phase II trial of MEDI-6012 in coronary artery disease

Matinas BioPharma files IND application with FDA for MAT-2501

Fibrocell and Intrexon to address chronic inflammatory and degenerative diseases of the joint

Enrollment complete in phase I trial of AVXS-101 in spinal muscular atrophy type 1

Novel muscarinic receptor modulator demonstrates a positive profile in vivo and in vitro

Roche starts phase I trial of spinal muscular atrophy candidate RO-7034067

Merck KGaA, Pfizer and Syndax to evaluate avelumab and entinostat in ovarian cancer

Baxalta and Symphogen form immuno-oncology collaboration

Merck & Co. patents nAChR alpha7 PAMs

Yuma Therapeutics and The Brigham and Women's Hospital develop HSP90 inhibitors

Emulate develops Small Airway Lung-Chip

KineMed and Pfizer establish biomarker discovery collaboration

Additional gene variants identified for AMD

Yisheng Biopharma releases phase I topline results for PIKA rabies vaccine

Higher doses of laquinimod discontinued in two MS trials following cardiovascular events

Simoctocog alfa now available in U.S.

FDA grants priority review to Gilead's NDA for sofosbuvir/velpatasvir

Sprouty has an atypical role as an oncogene in colorectal cancer

University of Virginia's artificial pancreas technology to enter pivotal trials in type 1 diabetes

Panasonic Healthcare completes acquisition of Bayer AG's Diabetes Care business

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...